Breaking the $40 per gram barrier for mAbs with EnzeneX™

Revolutionize Biologic Drug Manufacturing with EnzeneX™

Our fully-connected continuous manufacturing™ offers an innovative alternative to conventional fed-batch processes, especially for complex biologics. EnzeneX™ addresses these inefficiencies with a streamlined, automated continuous process from upstream to downstream.

Key benefits of EnzeneX™:

• Cost Efficiency: Achieve production costs under $40 per gram for monoclonal antibodies (mAbs), a significant reduction compared to traditional fed-batch processes.
• Enhanced Productivity: Experience 5-10 times higher productivity with increased cell densities and viability, leading to greater yields and faster production times.
• Streamlined Processes: Seamlessly integrate upstream and downstream operations, eliminating bottlenecks and reducing operational complexities.
• Reduced Footprint: Minimize facility size and capital expenditure with smaller bioreactors and fewer hold tanks.
• Complex Biologics Manufacturing: Efficiently produce complex biologics, including bi- and tri-specific molecules, expanding therapeutic possibilities.
• Proven Success: Commercially validated platform with successful launches of biosimilar mAbs in India and upcoming launches in the US and EU.

Embrace the future of biomanufacturing with EnzeneX™. Learn more on how EnzeneX™ is revolutionizing biopharmaceutical production, ensuring quality and accessibility for patients worldwide.